April 30, 2021 Hadean Ventures is a fast-growing life science fund manager that invests in…
Continue Reading-
Safety Monitoring Committee Approves 7 MBq as Recommended Clinical Dose for Radspherin®
Safety Monitoring Committee Approves 7 MBq as Recommended Clinical Dose for Radspherin® in the Ongoing…
Continue Reading -
STEP PHARMA
Step Pharma is developing novel therapeutics that inhibit the enzyme...
Continue Reading -
Step Pharma Raises EUR35 Million in Series B Financing to Advance First in Class CTPS1 inhibitor into the Clinic in T Cell Malignancies
Archamps, France, 24 March 2021 Step Pharma, a biotech company developing novel drugs for oncology…
Continue Reading -
Oncoinvent Announces Progression of Radspherin® to Third Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial
Oncoinvent Announces Progression of Radspherin® to Third Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial…
Continue Reading -
Pipeline Therapeutics Completes $80 Million Series C Financing
Financing to advance two clinical programs and accelerate discovery efforts SAN DIEGO, February 11, 2021…
Continue Reading -
Ekspertenes biotekfavoritter i urolige tider, e24.no
Ekspertenes biotekfavoritter i urolige tider – E24 Ina Vedde-Fjærestad Publisert: Publisert: 5. februar 2021 Etter…
Continue Reading -
Gesynta Pharma initiates Phase II study of its first-in-class drug candidate GS- 248 in patients with systemic sclerosis
Stockholm, Sweden, January 26, 2020 – Gesynta Pharma AB today announced that the first patients…
Continue Reading -
Abliva appoints Ellen Donnelly as new CEO as they enter a new development stage
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of…
Continue Reading -
Oncoinvent Announces Advancement of Radspherin® to Final Dose Level Cohort in Ongoing RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients
Safety Monitoring Committee review of third dose-level cohort allows progression of Phase 1 RAD-18-002 study…
Continue Reading